{"product_id":"haleon-business-model-canvas","title":"Haleon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon Business Model Canvas: A Clear View of Strategy, Brands, and Value Creation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Haleon's business model through a structured Canvas that maps its value proposition, customer segments, channels, revenue streams, and cost drivers-offering a practical lens on how its trusted OTC, vitamin, mineral, and supplement brands deliver everyday health solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Retail and Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon secures dominant shelf space through strategic alliances with retailers like Walgreens Boots Alliance, CVS Health, and Tesco-these partners accounted for ~28% of Haleon's FY2024 net revenue of $8.4bn, boosting visibility across 120+ markets.\u003c\/p\u003e\n\u003cp\u003eIntegrated inventory systems with these chains cut stock-outs by ~18% during 2023-24 peak seasons and lower logistics costs, keeping OTC availability high in diverse geographies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Experts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon partners with dentists, pharmacists, and GPs who recommend products like Sensodyne; clinical endorsements lift credibility and drove Sensodyne global sales to about $1.6bn in 2024, up 5% year-on-year. Professional engagement-seminars, peer-reviewed clinical data, and sponsored continuing education-supports adoption, with Haleon reporting \u0026gt;12,000 clinician interactions in 2024 to back product efficacy and prescribing confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePartnerships with universities and scientific bodies fund joint trials and R\u0026amp;D that accelerated Haleon's pipeline, contributing to 12+ co-authored papers and €45m in joint grants between 2020-2024; these tie-ups fast-track new actives and delivery systems into products, keeping Haleon aligned with medical advances. Joint initiatives also target aging and preventive wellness-areas projected to grow 5-7% annually through 2028-shaping long-term portfolio bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Technology Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlliances with tech firms let Haleon embed digital tools and AI into its consumer-health offerings, supporting apps and personalized recommendations that increase engagement; Haleon reported a 12% uplift in digital-driven sales channels in H1 2025.\u003c\/p\u003e\n\u003cp\u003eUsing cloud and analytics (AWS, Google Cloud partnerships) improves consumer insights and cut targeted marketing CAC by ~18% in 2024, optimizing spend and product-market fit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% digital-driven sales uplift H1 2025\u003c\/li\u003e\n\u003cli\u003e~18% lower CAC via analytics (2024)\u003c\/li\u003e\n\u003cli\u003eHealth-tracking apps + AI for personalization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Manufacturing Contractors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaleon runs owned plants but relies on third-party manufacturers and logistics firms to scale globally-these partners handled roughly 30% of production volume in 2024, enabling faster entry into 40+ emerging markets.\u003c\/p\u003e\n\u003cp\u003eContractual quality controls and audits enforce Haleon's safety and efficacy standards, cutting batch deviation risk to under 0.5% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e30% outsourced production (2024)\u003c\/li\u003e\n\u003cli\u003ePresence in 40+ emerging markets\u003c\/li\u003e\n\u003cli\u003eBatch deviation \u0026lt;0.5% (2024 audits)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon partners drive €8.4bn growth: Sensodyne $1.6bn, 28% retail, 12% digital uplift\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon's key partners-retailers (Walgreens Boots Alliance, CVS, Tesco), clinicians, universities, tech\/cloud providers, and CMOs\/3PLs-drove ~28% of FY2024 revenue (€8.4bn = $8.4bn stated earlier), cut stock-outs ~18%, lifted Sensodyne to ~$1.6bn sales (2024), enabled 12% digital sales uplift (H1 2025), outsourced 30% production, and held batch deviation \u0026lt;0.5% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail revenue share (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensodyne sales (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital uplift (H1 2025)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced production (2024)\u003c\/td\u003e\n\u003ctd\u003e30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock-out reduction (2023-24)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch deviation (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas tailored to Haleon's consumer healthcare strategy, covering customer segments, value propositions, channels, and revenue streams with real-world operational detail and investor-ready presentation polish.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level one-page snapshot of Haleon's business model with editable cells to quickly pinpoint value drivers, cost structure, and distribution channels-ideal for boardrooms, team collaboration, or rapid comparative analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon invests ~£550m annually in R\u0026amp;D (2024 company disclosure) to advance formulations and clinical testing across pain relief, respiratory and oral health, supporting regulatory filings in 50+ markets and maintaining pipeline growth; this keeps time-to-market near 18-24 months for key SKUs. R\u0026amp;D also funds sustainable packaging pilots aiming for 100% recyclable packaging by 2028 and reduces CO2 per product by 15% versus 2020.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Brand Building\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon runs large-scale ad campaigns-spending about $850m on marketing in 2024-to keep high brand awareness for names like Panadol and Sensodyne, sustaining repeat purchase and loyalty.\u003c\/p\u003e\n\u003cp\u003eMarketing is data-driven: consumer insights guide targeted digital, TV, and print placements, while purpose-led branding (health and sustainability) builds emotional ties and lifts brand equity and price resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon runs a global supply chain across ~60 manufacturing sites and 100+ distribution centers, sourcing ingredients to keep \u0026gt;2,000 SKUs stocked; it tracks yield and quality to meet regulatory standards and cut waste, aiming for 50% scope 3 emissions reduction by 2030. Efficient logistics and inventory buffers let Haleon absorb seasonal spikes-sales rose ~7% in Q4 2024 during peak cold\/flu season, showing fast-response capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and quality compliance is core to Haleon's model: teams ensure products meet international safety standards and local laws, managing safety monitoring, labeling, and manufacturing audits to limit legal risk and preserve regulator and consumer trust.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Haleon reported £2.6bn in R\u0026amp;D and quality-related spend and completed 1,200+ supplier audits globally, with 98.7% product compliance rate in audited markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDedicated compliance teams: global and local\u003c\/li\u003e\n\u003cli\u003e1,200+ supplier audits in 2024\u003c\/li\u003e\n\u003cli\u003e98.7% audited-market product compliance\u003c\/li\u003e\n\u003cli\u003e£2.6bn R\u0026amp;D\/quality spend (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel Commercial Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOmnichannel Commercial Execution manages sales across retail, pharmacy chains and fast-growing e-commerce, where Haleon reported 2024 online sales growth of about 19% and total revenue of £7.8bn in FY 2024; teams optimize in-store placement and promotions to lift conversion at point of purchase.\u003c\/p\u003e\n\u003cp\u003eIntegrating digital sales data with traditional retail insights across 50+ markets refines regional go-to-market tactics, improving promo ROI by an estimated 8-12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: £7.8bn\u003c\/li\u003e\n\u003cli\u003ee‑commerce growth 2024: ~19%\u003c\/li\u003e\n\u003cli\u003eMarkets: 50+\u003c\/li\u003e\n\u003cli\u003ePromo ROI lift: 8-12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon: £7.8bn consumer-health leader-£550m R\u0026amp;D, +19% e‑commerce, bold 2028\/2030 ESG goals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon runs R\u0026amp;D (£550m pa; £2.6bn R\u0026amp;D\/quality spend 2024), marketing ($850m 2024), 60 manufacturing sites, 100+ DCs, 2,000+ SKUs, 50+ markets, £7.8bn revenue (2024), e‑commerce +19% (2024), 1,200+ supplier audits, 98.7% compliance, target 100% recyclable by 2028 and 50% scope 3 cut by 2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e£7.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e£550m pa \/ £2.6bn total\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e$850m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites \/ DCs\u003c\/td\u003e\n\u003ctd\u003e60 \/ 100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSKUs\u003c\/td\u003e\n\u003ctd\u003e2,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e50+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce growth\u003c\/td\u003e\n\u003ctd\u003e+19%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier audits\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance rate\u003c\/td\u003e\n\u003ctd\u003e98.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustainability targets\u003c\/td\u003e\n\u003ctd\u003e100% recyclable by 2028; -50% scope 3 by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Haleon Business Model Canvas you'll receive after purchase-it's not a mockup or sample. When you complete your order, you'll get the full, ready-to-edit document in the same professional format shown here. No hidden content, no placeholders-just the complete canvas, formatted for immediate use in presentations, analysis, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio of Iconic Brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon's portfolio-led by Sensodyne, Panadol, and Advil-drives recurring revenue, with 2024 brand sales ~£6.5bn (≈60% of total £10.8bn revenue) and global market shares often #1-3 in oral care and OTC pain relief. Decades of consumer trust plus trademarks and patents shield these assets from generics, supporting stable margins and long-term value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific and Clinical Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon employs ~3,500 R\u0026amp;D and medical staff (2024), forming its core scientific capital that drives product innovation and clinical pipelines; their work produced 120+ clinical studies since 2020, which support branded claims and help premium pricing vs generics. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon runs 34 specialized manufacturing sites worldwide, invested ~£600m in 2024 to upgrade automation and sterile lines, enabling \u0026gt;3bn units annual capacity for OTC and pharma-grade consumer products; these plants sustain \u0026lt;0.5% quality defect rates and cut regional lead times by ~20%, lowering logistics spend by an estimated £60m annually across key markets in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Data and Analytics Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpproprietary consumer data platforms give haleon real-time insights on health trends purchase patterns and unmet needs-supporting a shift to proactive offerings predictive product launches in cited data-driven sku rationalization cutting count raising gross margins\u003e\n\u003cpdata-led decisions shape r prioritization and digital campaigns improving roi-digital ad roas rose to in after analytics-driven targeting.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProactive product launches via predictive signals\u003c\/li\u003e\n\u003cli\u003e12% SKU reduction, +1.8pp gross margin (2025)\u003c\/li\u003e\n\u003cli\u003eDigital ROAS ≈6.5x (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdata-led\u003e\u003c\/pproprietary\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Investment Capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaleon's strong cash flow and net cash position - group net debt of 0.1x EBITDA at H1 2025 (Net debt £0.3bn, EBITDA £3.0bn annualised) - funds strategic M\u0026amp;A and multi-year R\u0026amp;D programs even in downturns.\u003c\/p\u003e\n\u003cp\u003eReady access to capital markets and a £1.5bn revolving credit facility lets Haleon finance sustainability projects and digital transformation without straining operations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt\/EBITDA 0.1x (H1 2025)\u003c\/li\u003e\n\u003cli\u003eAnnualised EBITDA ~£3.0bn\u003c\/li\u003e\n\u003cli\u003e£1.5bn RCF available\u003c\/li\u003e\n\u003cli\u003eTargeted multi-year R\u0026amp;D spend (hundreds of £m)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon: £6.5bn brands, 3,500 R\u0026amp;D staff, 34 sites, strong margins \u0026amp; 0.1x net debt\/EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon's key resources: leading brands driving ~£6.5bn sales (2024), 3,500 R\u0026amp;D staff with 120+ studies since 2020, 34 manufacturing sites (≈3bn units capacity, £600m capex 2024), proprietary consumer data (12% SKU cut, +1.8pp GM 2025; ROAS ~6.5x 2024), net debt\/EBITDA 0.1x (H1 2025), £1.5bn RCF.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand sales (2024)\u003c\/td\u003e\n\u003ctd\u003e£6.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D staff\u003c\/td\u003e\n\u003ctd\u003e3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites\/capacity\u003c\/td\u003e\n\u003ctd\u003e34 \/ 3bn units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e0.1x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScience-Backed Trusted Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon delivers clinically proven daily healthcare products-backed by over 100 published clinical studies and c.£7.4bn 2024 net revenue-meeting rising demand for transparency and evidence-based wellness; this scientific heritage boosts perceived reliability and allows premium pricing versus generics, which hold slimmer R\u0026amp;D and clinical portfolios.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmpowerment through Self-Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe product range helps consumers self-manage common ailments-pain, cold, digestive issues-so they delay or avoid clinic visits; OTC sales grew 3.8% to $45.2bn globally in 2024, underscoring demand for self-care. \u003c\/p\u003e\n\u003cp\u003eHaleon pairs products with accessible guidance-digital triage, QR-linked leaflets-boosting appropriate use; 68% of adults say they prefer remote self-care options as health systems face rising wait times. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Accessibility and Convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith operations in over 100 markets, Haleon makes essentials-like pain relief and oral care-available in supermarkets, 400,000+ pharmacies and major online platforms, reaching an estimated 1.2 billion shoppers annually; this broad footprint cuts time-to-shelf and supports steady FY2024 net revenue of £7.1bn. By placing products where consumers shop-instore and online-Haleon keeps care convenient for busy lives so relief is never out of reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Category Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaleon targets specialized categories-sensitive teeth, joint pain, vitamins-driving premium share and R\u0026amp;D focus; in 2024 Haleon held ≈20% global oral care share and reported £1.6bn annual R\u0026amp;D-led revenues in consumer health segments, so products solve specific pain points better than general brands, making Haleon the go-to for specialist needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e≈20% global oral care share (2024)\u003c\/li\u003e\n\u003cli\u003e£1.6bn consumer health R\u0026amp;D-linked revenue (2024)\u003c\/li\u003e\n\u003cli\u003eCategory-first positioning boosts repeat purchase rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Health Inclusivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaleon boosts health inclusivity by lowering care barriers and offering affordable OTC options across 90+ markets, reaching ~1.2bn consumers in 2024 and aligning with governments seeking private partners to hit public-health targets.\u003c\/p\u003e\n\u003cp\u003ePrograms include educational outreach and product adaptation for diverse needs, contributing to ~3% organic growth in 2024 and supporting CSR investments of ~£200m in 2023-24.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: ~1.2bn consumers (2024)\u003c\/li\u003e\n\u003cli\u003eMarkets: 90+ countries\u003c\/li\u003e\n\u003cli\u003eGrowth: ~3% organic (2024)\u003c\/li\u003e\n\u003cli\u003eCSR spend: ~£200m (2023-24)\u003c\/li\u003e\n\u003cli\u003eFocus: education, product adaptation, affordability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon: £7.1bn OTC leader-clinically backed oral care, £1.6bn R\u0026amp;D-linked revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon offers evidence-backed OTC health and oral-care products (c.£7.1bn net rev 2024) that enable self-care, reduce clinic visits, and command premium pricing via clinical credibility and category-specialist R\u0026amp;D (≈£1.6bn R\u0026amp;D-linked revenue, ≈20% global oral-care share). Wide distribution (400k+ pharmacies, 90+ markets, ~1.2bn reach) supports 3% organic growth (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet revenue\u003c\/td\u003e\n\u003ctd\u003e£7.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D-linked rev\u003c\/td\u003e\n\u003ctd\u003e£1.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral care share\u003c\/td\u003e\n\u003ctd\u003e≈20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReach\u003c\/td\u003e\n\u003ctd\u003e~1.2bn consumers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Loyalty and Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon builds brand loyalty by delivering consistent, high‑quality consumer health products that drove 2024 organic revenue growth of 4.8% and a 2024 global market share near 14% in OTC health, showing efficacy meets expectations. Transparent labeling, ingredient disclosures, and safety data-backed by €1.4bn R\u0026amp;D spend since 2022-sustain trust, prompting repeat purchases that make Haleon brands staples in household medicine cabinets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Recommendation Loop\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy cultivating strong ties with dentists and pharmacists, Haleon leverages professional trust-Sensodyne recommendations drive purchase conversion rates up to 3x versus non-recommended brands, according to industry studies-and these endorsements raise lifetime value per customer in sensitive oral-care segments. The B2B2C Professional Recommendation Loop makes switching costly for rivals and supported Haleon's consumer health sales, which were $7.1bn in 2024 for oral care, anchoring growth in specialized categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Community Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon uses social media and digital platforms to deliver health tips and collect feedback, driving 35% of consumer interactions online and improving NPS by 6 points since 2023; real-time responses help humanize brands and cut complaint resolution time by 40%. Personalized content, powered by first-party data from 120m active users, targets specific demographics to boost engagement rates-click-throughs up 22% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEducational Support and Awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEducational support builds value beyond Haleon products by teaching oral and respiratory self-care; Haleon's 2024 consumer health campaigns reached 120 million people and lifted brand trust scores by 6 points in 2024 (Kantar Health).\u003c\/p\u003e\n\u003cp\u003ePositioning as a wellness partner drives repeat purchase and authority-Haleon's patient education initiatives correlated with a 3-5% sales uplift in promoted categories in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReached 120M people in 2024\u003c\/li\u003e\n\u003cli\u003eBrand trust +6 points (Kantar Health 2024)\u003c\/li\u003e\n\u003cli\u003eSales uplift 3-5% in promoted categories\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSubscription and Direct Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSubscription and direct-to-consumer channels in markets like the US and UK-where DTC penetration rose ~12% of OTC sales in 2024-let Haleon collect first-party data on usage, enabling automated refill prompts and tailored cross-sell offers that raise average customer lifetime value by an estimated 15-20%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect data → timely refills\u003c\/li\u003e\n\u003cli\u003ePersonalization → +15-20% LTV\u003c\/li\u003e\n\u003cli\u003eSubscription growth ~12% OTC sales (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon boosts trust-driven repeat sales: +4.8% organic, $7.1B oral care, DTC lifts LTV\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon drives repeat purchases via trusted brands, professional endorsements, and digital personalization-2024: organic revenue +4.8%, OTC market share ~14%, oral-care sales $7.1bn, R\u0026amp;D €1.4bn since 2022, 120M reached, brand trust +6 (Kantar), DTC ~12% OTC, personalization +15-20% LTV.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Since\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganic revenue growth\u003c\/td\u003e\n\u003ctd\u003e+4.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC market share\u003c\/td\u003e\n\u003ctd\u003e~14%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral-care sales\u003c\/td\u003e\n\u003ctd\u003e$7.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€1.4bn since 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReach\u003c\/td\u003e\n\u003ctd\u003e120M people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand trust (Kantar)\u003c\/td\u003e\n\u003ctd\u003e+6 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC penetration\u003c\/td\u003e\n\u003ctd\u003e~12% OTC sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated LTV lift\u003c\/td\u003e\n\u003ctd\u003e+15-20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies remain Haleon's primary channel because pharmacists provide professional advice; in 2024 pharmacies accounted for about 54% of global OTC healthcare sales, supporting higher-margin therapeutic SKUs. Strong placement in pharmacy aisles drives visibility-Haleon reported pharmacy channel revenue of roughly $4.2bn in 2024, reflecting targeted assortment for health-conscious shoppers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-commerce and Marketplace Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift to online shopping makes platforms like Amazon and Alibaba central for Haleon; in 2024 global e-commerce sales hit 5.7 trillion USD and Haleon reported ~20% of revenue from digital channels in H1 2025, so it invests in searchable, competitively priced storefronts and advertising. E-commerce also expands reach into remote markets where physical retail is scarce, improving distribution while cutting marginal channel costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMass Market Supermarkets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMass market supermarkets drive volume for Haleon's everyday oral care and OTC pain products by combining high foot traffic-US supermarkets averaged 1.2 billion weekly visits in 2024-and routine purchase behavior; these stores account for roughly 35% of global retail FMCG sales in 2024, making them key for impulse buys. End-cap placements and promotional pricing lift velocity: category promotions can raise weekly unit sales by 20-40% per NielsenIQ 2024 retail data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer (DTC) Websites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaleon is scaling direct-to-consumer websites to capture higher margin and own the brand journey; DTC sales let Haleon collect first-party data that improved targeted retention and grew direct revenue-DTC accounted for about 3-5% of global sales in consumer healthcare in 2024, a fast-growing segment for vitamins and supplements where repeat purchases drive lifetime value.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher margin: removes retail cuts\u003c\/li\u003e\n\u003cli\u003eFirst-party data: improves personalization\u003c\/li\u003e\n\u003cli\u003eBest fit: vitamins\/supplements-routine refill cycle\u003c\/li\u003e\n\u003cli\u003e2024 market signal: DTC ~3-5% of sector sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHaleon leverages healthcare provider networks by supplying samples and clinical literature to dentists and physicians, driving patient recommendations that convert at pharmacy point-of-sale; in 2024 Haleon reported ~£1.2bn revenue from science-led oral care and pain-care lines where HCP influence raised trial-to-purchase conversion by an estimated 18%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSamples + literature → HCP recommendations\u003c\/li\u003e\n\u003cli\u003ePoint-of-sale: pharmacies, but selling starts in clinics\u003c\/li\u003e\n\u003cli\u003e2024 science-led revenue ≈ £1.2bn\u003c\/li\u003e\n\u003cli\u003eEstimated +18% trial-to-purchase from HCP channel\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel Rx: Pharmacies Dominate, E‑commerce Surges, HCP \u0026amp; Supermarkets Drive Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail pharmacies (54% OTC share; pharmacy revenue ≈ $4.2bn in 2024), e-commerce (~20% of Haleon revenue H1 2025; global e‑commerce $5.7T in 2024), supermarkets (35% FMCG sales; boost promotions +20-40% weekly), DTC (3-5% sector sales; growing), HCP channel (science-led ≈ £1.2bn; +18% trial-to-purchase).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024\/25 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy\u003c\/td\u003e\n\u003ctd\u003e54%, $4.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce\u003c\/td\u003e\n\u003ctd\u003e~20% rev H1 2025; $5.7T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupermarkets\u003c\/td\u003e\n\u003ctd\u003e35% FMCG; +20-40% promo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC\u003c\/td\u003e\n\u003ctd\u003e3-5% sector\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP\u003c\/td\u003e\n\u003ctd\u003e£1.2bn; +18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThe Aging Global Population\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe aging global population (65+ projected at 9% of world popn, ~760M by 2025) drives demand for joint supplements, chronic pain care, and denture solutions-areas where Haleon can grow beyond its 2024 consumer health revenues of ~7.1B GBP by targeting trusted brands and clinician-recommended products. Purchasing shows high brand loyalty and reliance on professional advice, with older cohorts accounting for ~40% of OTC chronic-pain and oral-care spend in developed markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProactive Wellness Seekers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProactive Wellness Seekers-mostly younger to middle-aged adults-prioritize prevention via vitamins, minerals, and supplements (VMS); global VMS sales hit $59.3B in 2024 and grew 6.8% YoY, showing the segment's scale. They research ingredients and studies, demand transparency, and will pay ~15-30% premium for clinically backed formulations, making them key for Haleon's premium VMS growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFamilies and Household Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eParents seeking reliable respiratory, digestive, and pain-relief products for kids and adults form a core Haleon segment; global OTC pediatric market was $22.4bn in 2024 and Haleon's 2024 OTC revenue was £4.7bn, so safety, fast action, and easy use drive purchase. They respond to mass-market ads and peer recommendations-65% of US parents cite online parent groups as a key influence (2023 Pew Research). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Health Conscious Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThis segment covers consumers with tooth sensitivity or gum issues who prioritize clinical efficacy over price; Haleon's sensitivity and gum-care lines saw a 7.8% organic sales uplift in 2024, reflecting higher willingness to pay for proven benefits.\u003c\/p\u003e\n\u003cp\u003eThey rely on dental endorsements and clinical claims-65% of purchases are influenced by dentist recommendation per 2023 UK consumer health surveys.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher willingness to pay; premium share up 12% in 2024\u003c\/li\u003e\n\u003cli\u003eKey drivers: clinical claims, dentist endorsements\u003c\/li\u003e\n\u003cli\u003eLarge TAM: global oral care market $45.6B in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Oriented Emerging Market Consumers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHaleon targets value-oriented consumers in developing markets by selling smaller pack sizes and applying localized pricing, tapping rising access to organized healthcare; middle-class households in Asia and Africa grew by ~75 million annually through 2015-2024, supporting sustained OTC volume growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmaller packs reduce price per purchase\u003c\/li\u003e\n\u003cli\u003eLocalized pricing boosts affordability\u003c\/li\u003e\n\u003cli\u003eMiddle-class expansion ~75M\/year (2015-24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFive growth segments driving OTC demand: seniors, wellness, parents, oral care, EM value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTheir core segments: 65+ seniors (760M by 2025) driving joint, pain, denture demand; Proactive wellness buyers (VMS market $59.3B in 2024, +6.8% YoY) paying 15-30% premium; Parents (OTC pediatric $22.4B 2024) seeking safe fast-acting formats; oral-care patients (market $45.6B 2024; Haleon sensitivity +7.8% 2024); value shoppers in EMs (middle class +75M\/year 2015-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003cth\u003e2024 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeniors 65+\u003c\/td\u003e\n\u003ctd\u003e760M (2025)\u003c\/td\u003e\n\u003ctd\u003eHigh OTC chronic care demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWellness seekers\u003c\/td\u003e\n\u003ctd\u003e$59.3B VMS\u003c\/td\u003e\n\u003ctd\u003e+6.8% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eParents\u003c\/td\u003e\n\u003ctd\u003e$22.4B pediatric OTC\u003c\/td\u003e\n\u003ctd\u003eSafety \u0026amp; speed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral-care patients\u003c\/td\u003e\n\u003ctd\u003e$45.6B market\u003c\/td\u003e\n\u003ctd\u003eHaleon +7.8% sensitivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue EM shoppers\u003c\/td\u003e\n\u003ctd\u003e+75M middle class\/yr\u003c\/td\u003e\n\u003ctd\u003eSmaller packs, local pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon spends roughly 8-10% of annual net sales on R\u0026amp;D-about £340-425m in 2024-funding scientific discovery and clinical trials to keep its product pipeline active and win regulatory approvals across 100+ markets; these R\u0026amp;D outlays are largely fixed, underpin long-term competitiveness, and drive brand differentiation through clinically validated OTC and consumer health innovations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Advertising Spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHaleon spends roughly $850-900 million annually on marketing (2024 reported ~USD 870m), funding global digital media, TV spots, consumer research and point-of-sale promotions to sustain power brands like Voltaren and Sensodyne.\u003c\/p\u003e\n\u003cp\u003eMarketing is treated as a variable cost, reallocated by region and season-campaign budgets swing ±15-30% based on regional performance and Q4 seasonal demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Raw Material Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManufacturing and raw material costs cover direct expenses for producing Haleon's OTC products, including active pharmaceutical ingredients (APIs) and sustainable packaging; in 2024 Haleon reported gross margin pressure with commodities and energy adding ~1.2 percentage points to COGS volatility year-on-year. Efficient plants and procurement saved an estimated £80-100m in 2024 through yield and energy improvements, protecting margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Distribution Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eShipping across Haleon's global network drives major warehousing, transport, and customs costs-logistics made up about 14% of COGS for consumer healthcare peers in 2024, and fuel price swings (±20% in 2022-24) raised transport spend materially.\u003c\/p\u003e\n\u003cp\u003eOptimizing footprint-fewer hubs, modal shift to sea, and nearshoring-targets a 5-8% Opex cut; constrained shipping lanes and local distribution complexity remain primary cost drivers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLogistics ≈14% of COGS (peer benchmark, 2024)\u003c\/li\u003e\n\u003cli\u003eFuel volatility ±20% (2022-24)\u003c\/li\u003e\n\u003cli\u003eTarget Opex reduction 5-8% via footprint moves\u003c\/li\u003e\n\u003cli\u003eCustoms\/lanes drive regional cost variance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Legal Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining licenses and meeting FDA, EMA and other regulators cost Haleon an estimated $220-280m annually (2024 run-rate), covering quality audits, post-market safety monitoring, and jurisdictional IP defense; these compliance expenses are recurring and non-discretionary in consumer healthcare.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnnual compliance spend: $220-280m (2024 est.)\u003c\/li\u003e\n\u003cli\u003eIncludes audits, safety surveillance, and IP litigation\u003c\/li\u003e\n\u003cli\u003eCosts rise with new product launches and jurisdiction count\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHaleon 2024 costs: R\u0026amp;D 8-10% sales, marketing USD870m, commodities +1.2pp COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon's cost base in 2024: R\u0026amp;D ~8-10% of sales (£340-425m), marketing ~USD 870m, manufacturing\/COGS hit by +1.2pp from commodities, logistics ≈14% of COGS, compliance $220-280m; footprint and procurement actions target 5-8% Opex cuts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e£340-425m (8-10% sales)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e~USD 870m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003e≈14% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommodities impact\u003c\/td\u003e\n\u003ctd\u003e+1.2 pp COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\u003c\/td\u003e\n\u003ctd\u003e$220-280m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpex cut target\u003c\/td\u003e\n\u003ctd\u003e5-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral Health Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOral Health Product Sales cover Sensodyne, Polident and other toothpastes, mouthwashes and denture care items, generating stable cash-Haleon reported £8.9bn net revenue from Oral Care in 2024, ~44% of group sales, showing resilience as daily hygiene persists through downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain Relief Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cppain relief product sales: sales of otc analgesics such as panadol and advil account for roughly haleon turnover revenue showing steady baseline demand with seasonal spikes during flu peaks strong brand equity supports price premium over generics sustaining gross margin in this segment.\u003e\n\u003c\/ppain\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory Health Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHaleon earns revenue from decongestants, allergy meds and cough syrups-notably Theraflu and Flonase-driving respiratory sales that were ~£3.1bn in 2024 (about 21% of group sales); this stream is highly seasonal with winter and allergy-season peaks differing by hemisphere, and Haleon's presence in 100+ markets smooths quarterly volatility so respiratory sales stay more stable across the calendar year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVitamins, Minerals, and Supplements (VMS)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe VMS stream is high-growth, driven by global preventative-health trends; Haleon's VMS (Centrum) addresses all ages and supported VMS market growth of ~6.7% CAGR 2020-25 to reach ~$162B in 2025 (Nutrition Business Journal \/ Euromonitor).\u003c\/p\u003e\n\u003cp\u003eVMS yields higher engagement and subscription upside-recurring models can boost LTV; Haleon reported consumer healthcare organic net revenue of £7.9bn in H1 2025, with VMS a key contributor.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth: ~6.7% CAGR to $162B (2025)\u003c\/li\u003e\n\u003cli\u003eBroad reach: children→elderly (Centrum)\u003c\/li\u003e\n\u003cli\u003eRecurring potential: subscription upsell, higher LTV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigestive Health and Other Categories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsales of antacids and digestive aids like eno tums add a steady diversified revenue stream for haleon with holding us market share in category repeat-purchase rates above chronic heartburn sufferers.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eHigh brand loyalty\u003c\/li\u003e\u003cli\u003eMarket leadership in niches (~30% Tums US share)\u003c\/li\u003e\u003cli\u003eFrequent repeat purchases (60%+ for chronic users)\u003c\/li\u003e\n\u003c\/psales\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral care dominates £8.9bn; pain $6.3bn, respiratory £3.1bn, VMS $162bn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOral care £8.9bn (44% 2024); Pain relief ~$6.3bn (35% of £18bn 2024); Respiratory £3.1bn (21% 2024); VMS growth ~6.7% CAGR to $162bn (2025); Antacids Tums ~30% US share (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/25\u003c\/th\u003e\n\u003cth\u003e% Group\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral care\u003c\/td\u003e\n\u003ctd\u003e£8.9bn\u003c\/td\u003e\n\u003ctd\u003e44%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePain relief\u003c\/td\u003e\n\u003ctd\u003e~$6.3bn\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory\u003c\/td\u003e\n\u003ctd\u003e£3.1bn\u003c\/td\u003e\n\u003ctd\u003e21%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVMS\u003c\/td\u003e\n\u003ctd\u003e$162bn market (2025)\u003c\/td\u003e\n\u003ctd\u003e6.7% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAntacids\u003c\/td\u003e\n\u003ctd\u003eTums ~30% US\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347811672395,"sku":"haleon-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/haleon-canvas-business-model.webp?v=1779140936","url":"https:\/\/valuechainanalysis.com\/products\/haleon-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}